ATE429432T1 - Indazolderivate als faktor xa-inhibitoren - Google Patents

Indazolderivate als faktor xa-inhibitoren

Info

Publication number
ATE429432T1
ATE429432T1 AT04731155T AT04731155T ATE429432T1 AT E429432 T1 ATE429432 T1 AT E429432T1 AT 04731155 T AT04731155 T AT 04731155T AT 04731155 T AT04731155 T AT 04731155T AT E429432 T1 ATE429432 T1 AT E429432T1
Authority
AT
Austria
Prior art keywords
factor
compounds
formulae
chem
factor viia
Prior art date
Application number
AT04731155T
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
Volker Laux
Matthias Urmann
Armin Bauer
Hans Matter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE429432T1 publication Critical patent/ATE429432T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04731155T 2003-05-19 2004-05-05 Indazolderivate als faktor xa-inhibitoren ATE429432T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011303A EP1479675A1 (de) 2003-05-19 2003-05-19 Indazolderivate als Faktor Xa-Inhibitoren
PCT/EP2004/004753 WO2004101556A1 (en) 2003-05-19 2004-05-05 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
ATE429432T1 true ATE429432T1 (de) 2009-05-15

Family

ID=33040950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04731155T ATE429432T1 (de) 2003-05-19 2004-05-05 Indazolderivate als faktor xa-inhibitoren

Country Status (13)

Country Link
US (1) US7365088B2 (de)
EP (2) EP1479675A1 (de)
JP (1) JP4709763B2 (de)
AT (1) ATE429432T1 (de)
AU (1) AU2004238499A1 (de)
BR (1) BRPI0410430A (de)
CA (1) CA2528220A1 (de)
CL (1) CL2004001080A1 (de)
DE (1) DE602004020761D1 (de)
MX (1) MXPA05012346A (de)
PE (1) PE20050153A1 (de)
TW (1) TW200510400A (de)
WO (1) WO2004101556A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510742A (ja) * 2002-11-08 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼科組成物
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479677A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Neue Indolderivate als Faktor Xa-Inhibitoren
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
CA2537430A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
DE10342570A1 (de) 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
EP1568698A1 (de) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrolderivate als faktor-xa-inhibitoren
EP1571154A1 (de) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Derivate des Beta-Alanins als Hemmer des Faktors Xa
EP1737471A4 (de) * 2004-04-20 2010-08-25 Rnd Pharmaceuticals Pharmazeutische vorrichtungen und verfahren zur verwendung von lipophilen, mit silikon substituierten cyclooxygenase-2-selektiven nichtsteroidalen entzündungshemmern und derivaten
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2009023233A1 (en) 2007-08-14 2009-02-19 Concert Pharmaceuticals, Inc. Substituted oxazolidinone derivatives
EP2240452B1 (de) 2008-01-04 2019-05-29 Intellikine, LLC 1h-pyrazolo[3,4-d]pyrimidin-4-aminderivate als pi3-kinasenmodulatoren, ihre zusammensetzungen und anwendungen
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012153155A1 (en) 2011-05-06 2012-11-15 Egis Gyógyszergyár Nyilvãnosan Müködö Részvény-Társaság Process for the preparation of a rivaroxaban and intermediates formed in said process
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
CN109456205B (zh) * 2018-12-17 2021-09-21 石河子大学 以取代喹啉或异喹啉酰肼吡啶-n-氧化物为配体的水相体系中的n-芳基化方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
JP3655632B2 (ja) 1994-04-26 2005-06-02 アベンティス・ファーマスーティカルズ・インコーポレイテッド 第Ｘａ因子インヒビター
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP0987274A1 (de) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore
BR9917080A (pt) * 1998-12-23 2002-03-12 Du Pont Pharm Co Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
PL354998A1 (en) 1999-07-28 2004-03-22 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds
DE10014645A1 (de) 2000-03-24 2001-09-27 Merck Patent Gmbh Substituierte Biphenylderivate
CA2409762A1 (en) * 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
EP1217000A1 (de) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Faktor Xa und Faktor VIIa Inhibitoren
ATE524441T1 (de) * 2000-12-28 2011-09-15 Daiichi Seiyaku Co Vla-4-inhibitoren
EP1314733A1 (de) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indol-2-carbonsäureamide als Faktor-Xa-Hemmer
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479677A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Neue Indolderivate als Faktor Xa-Inhibitoren
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1568698A1 (de) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrolderivate als faktor-xa-inhibitoren
EP1571154A1 (de) 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Derivate des Beta-Alanins als Hemmer des Faktors Xa

Also Published As

Publication number Publication date
CL2004001080A1 (es) 2005-04-08
EP1628972A1 (de) 2006-03-01
CA2528220A1 (en) 2004-11-25
PE20050153A1 (es) 2005-04-25
TW200510400A (en) 2005-03-16
EP1479675A1 (de) 2004-11-24
JP2006528942A (ja) 2006-12-28
DE602004020761D1 (de) 2009-06-04
JP4709763B2 (ja) 2011-06-22
US7365088B2 (en) 2008-04-29
BRPI0410430A (pt) 2006-06-06
AU2004238499A1 (en) 2004-11-25
MXPA05012346A (es) 2006-05-25
WO2004101556A1 (en) 2004-11-25
EP1628972B1 (de) 2009-04-22
US20040235824A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
ATE429432T1 (de) Indazolderivate als faktor xa-inhibitoren
DE602004028367D1 (de) Neue indolderivate als faktor xa-inhibitoren
NO20032820D0 (no) Oksybenzamidderivater som faktor XA inhibitorer
MXPA04004797A (es) Indol-2-carboxamidas como inhibidores del factor xa.
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties